Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Future Medicinal Chemistry

• Publication date

  2017-03-06

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4155/fmc-2017-0009PMID 28263082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global vision of druggability issues: applications and perspectives.

  2017cited by this paper
• 2015 FDA drug approvals

  2016cited by this paper
• Twenty years on: the impact of fragments on drug discovery

  2016cited by this paper
• Types of Ubiquitin Ligases.

  2016cited by this paper
• A Generic Platform for Cellular Screening Against Ubiquitin Ligases

  2016cited by this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cited by this paper
• Targeting ubiquitination for cancer therapies.

  2015cited by this paper
• Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation

  2015cited by this paper
• 2.2 Å resolution cryo-EM structure of β-galactosidase in complex with a cell-permeant inhibitor

  2015cited by this paper
• Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

  2014cited by this paper
• SCF ubiquitin ligase-targeted therapies

  2014cited by this paper
• Molecular simulations with solvent competition quantify water displaceability and provide accurate interaction maps of protein binding sites.

  2014cited by this paper
• New insights into ubiquitin E3 ligase mechanism

  2014cited by this paper
• Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

  2013cited by this paper
• Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

  2012cited by this paper
• Will the ubiquitin system furnish as many drug targets as protein kinases?

  2010cited by this paper
• An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase

  2010cited by this paper
• Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases.

  2007cited by this paper
• Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

  2007cited by this paper

• Herpes simplex encephalitis due to a mutation in an E3 ubiquitin ligase

  2024cites this paper
• Degradation bottlenecks and resource competition in transiently and stably engineered mammalian cells

  2024cites this paper
• Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?

  2024cites this paper
• Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins

  2023cites this paper
• Beta-Transducin Repeats-Containing Proteins as an Anticancer Target

  2023cites this paper
• Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

  2022cites this paper
• The exploitation of host autophagy and ubiquitin machinery by Mycobacterium tuberculosis in shaping immune responses and host defense during infection

  2022cites this paper
• Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

  2021cites this paper
• E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

  2021cites this paper
• Protein Function | Allostery in Proteins: Canonical Models and New Insights

  2021cites this paper
• Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class

  2021cites this paper
• Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation

  2021cites this paper
• Emerging Strategies Targeting Catabolic Muscle Stress Relief

  2020cites this paper
• The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules

  2020cites this paper
• HECT E3 ubiquitin ligases – emerging insights into their biological roles and disease relevance

  2020cites this paper
• Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?

  2020cites this paper
• PROTAC-mediated crosstalk between E3 ligases.

  2019cites this paper
• Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery

  2019cites this paper
• Degradation of proteins by PROTACs and other strategies

  2019cites this paper
• Writing Histone Monoubiquitination in Human Malignancy—The Role of RING Finger E3 Ubiquitin Ligases

  2019cites this paper
• Welcome to Future Medicinal Chemistry volume 10.

  2018cites this paper
• RNA-modifying proteins as anticancer drug targets

  2018cites this paper
• A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders

  2018cites this paper
• Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation

  2017cites this paper
• Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli

  2017cites this paper